Zhuo-Wei Liu

ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health challenge. Its advanced stage, metabolic dysfunction-associated steatohepatitis (MASH), involves complex processes such as metabolic dysregulation, inflammation, and fibrosis. Existing treatments mainly target steatosis but have...